MFS Medifocus Inc

(NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA)

Medifocus Inc. (Medifocus or the Company) (TSX VENTURE:MFS)(OTCQX:MDFZF)
announces that it has completed its previously announced private placement. The
Company issued 13,056,997 units (each a Unit) at a price of $0.15 per Unit for
gross proceeds of $1,958,549.55. Each Unit is comprised of one common share (a
Common Share) and one Series D Common Share purchase warrant (a Warrant). Each
Warrant entitles the holder to purchase one additional Common Share at a price
of $0.20 for a period of 24 months following the completion of the Offering. If,
at any time prior to the warrants' expiration date, the daily volume weighted
average trading price of the Common Shares on the TSX Venture Exchange exceeds
$0.75 for at least 10 consecutive trading days, Medifocus may, within 30 days of
such occurrence, give an expiry acceleration notice to the holders of Warrants
and, if it does so, the Warrants will, unless exercised, expire on the 30th day
after the expiry acceleration notice is given. The Common Shares and Warrants
issued in connection with the private placement, and any Common Shares issued
upon the exercise of the Warrants, will have a hold period in Canada until May
15, 2013. 


In connection with the private placement, subject to compliance with applicable
securities legislation and TSX Venture Exchange policies, a 7% finder's fee was
paid on $7,500.00 of the gross proceeds for an aggregate finder's fee of
$525.00. 


The proceeds of this Offering will be primarily used to commercialize the newly
acquired Prolieve(R) line of business, for working capital and to continue
Medifocus' pivotal phase III clinical trials using Medifocus Microfocus APA 1000
System for the treatment of breast cancer (including all related professional
expenses).


About Medifocus 

Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array (APA) technology), which can precisely target and control microwave
energy to cause heating in cancerous tumors anywhere in the body reliably and
repeatedly. The ability to target tumors with a precision controlled dose of
heat can be used to destroy tumors at higher temperatures, to treat tumors in
combination with chemotherapy and/or radiation at moderate temperatures for
increased effectiveness and reduced toxicity and to trigger the targeted release
of therapeutic drugs and genes at tumor sites at lower temperatures. While the
core technology has been licensed from the Massachusetts Institute of
Technology, Medifocus has further refined the precision of the microwave
focusing and control ability and developed a commercial system dedicated
exclusively for the treatment of Breast Cancer. With the acquisition of
Prolieve(R), Medifocus now owns in addition, a revenue generating commercial BPH
heat treatment product generating cash flow to support the development and
commercialization of other catheter based or APA based external focused heat
systems for targeted thermotherapy of deep seated tumors anywhere in the body.
Please visit www.medifocusinc.com for more details.


Forward-Looking Statements and Information 

This news release contains "forward-looking statements" and "forward-looking
information", which may not be based on historical facts. Forward-looking
statements and forward-looking information, include, but are not limited to,
information and statements with respect to the expected use of the proceeds.
Forward-looking statements are frequently characterized by words such as "plan,"
"expect," "project," "intend," "believe," "anticipate", "estimate" and other
similar words, or statements that certain events or conditions "may" or "will"
occur. Forward-looking statements are based on the opinions and estimates of
management at the date the statements are made. Such forward-looking statements
and forward-looking information involve known and unknown risks, uncertainties
and other factors that may cause the actual results events or developments to be
materially different from any future results, events or developments expressed
or implied by such forward-looking statements or forward-looking information.
These factors should be considered carefully and readers are cautioned not to
place undue reliance on such forward-looking statements and forward-looking
information. Except as required by applicable securities laws, the Company
disclaims any obligation to update any such factors or to publicly announce the
results of any revisions to any of the forward-looking statements or
forward-looking information contained herein to reflect future results, events
or developments.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Medifocus Inc.
John Mon
Chief Operating Officer
(410) 290-5734
jmon@medifocusinc.com
www.medifocusinc.com

Grafico Azioni Medifocus (TSXV:MFS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Medifocus (TSXV:MFS)
Storico
Da Giu 2023 a Giu 2024